# US 2017/0362662 A1 · Novel rna-biomarker signature for diagnosis of prostate cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0362662 A1
- Document ID: US20170362662A1
- Status: Published application
- Kind: A1
- Application number: 15/532,381
- Filed: 2015-12-01
- Published: 2017-12-21
- Earliest claimed: 2014-12-01
- Assignees: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
- Applicants: Fraunhofer-Gesellschaft Zur FöRderung Der Angewandten Forschung E.V.
- Inventors: Friedemann Horn; Jörg Hackermüller; Sabina Christ; Kristin Reiche; Manfred Wirth; Michael Fröhner; Susanne Füssel
- Web page: https://patentgrep.com/patent/US20170362662A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61P 13/08: of the prostate
- A61P 35/00: Antineoplastic agents
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to the identification and selection of differentially expressed transcripts (biomarker) in tumour cells. Specific determination of the level of these biomarkers can be used for screening and diagnosis of prostate cancer. Clinical application of assays based on these biomarker help reduce the high number of false positives of current standard screening assays.

## Claims

### Claim 1

A method for the diagnosis of prostate cancer, comprising the steps of
a) analysing the expression levels of at least two nucleic acids in a sample of a patient, wherein said at least two nucleic acids are selected from at least two groups of nucleic acids, wherein said groups consist of:
Group 1: SEQ ID NO 1
Group 2: a splice variant of Ensembl gene ID ENSG00000245750.3 selected from the group consisting of SEQ ID NO: 4, 5, 6, 7, 8, 9 and 10
Group 3: a splice variant of Ensembl gene ID ENSG00000255545.3 selected from the group SEQ ID NO: 26, 27, 28 and 29
Group 4: SEQ ID NO 3 and 11
Group 5: SEQ ID NO 12
Group 6: SEQ ID NO 24
Group 7: SEQ ID NO 36
Group 8: SEQ ID NO 38
b) wherein, if the expression level of said at least two nucleic acids is above a defined threshold value, the sample is designated as prostate cancer positive.

### Claim 2 (depends on 1)

A method according to claim 1, wherein at least one of said at least two nucleic acids is selected from group 1 SEQ ID NO 1 and/or group 2 SEQ ID NO 4, 5, 6, 7, 8, 9 and 10.

### Claim 3 (depends on 1, 2)

A method according to claim 1 or 2, wherein the expression level of at least 5 nucleic acids are analysed, wherein said nucleic acids are selected from at least 5 different groups.

### Claim 4 (depends on 1)

A method according to claim 1, wherein the expression level of at least one nucleic acid from each of the eight groups is analyzed.

### Claim 5 (depends on 1, 2, 3, 4)

A method according to any of claims 1 to 4, wherein the sample is selected from the group comprising prostate tissue, biopsy material, lymph nodes, urine, ejaculate, blood, blood serum, blood plasma, circulating tumour cells in blood or lymph, any tissue suspected to contain metastases as well as any source that may contain prostate tumour cells or parts thereof, including vesicles like exosomes, micro vesicles, and others as well as free or protein-bound RNA molecules derived from prostate tumour cells.

### Claim 6 (depends on 1, 2, 3, 4)

A method according to any of claims 1 to 4, wherein the sample is a urine sample.

### Claim 7

A method according to any of the preceding claims, wherein the analysis of the expression level is performed by measuring the fluorescence of a labelled primer, labelled probe or a fluorescent detection agent.

### Claim 8

A method according to any of the preceding claims, wherein the analysis of the expression level is performed by qRT-PCR.

### Claim 9

A kit for the diagnosis of prostate cancer comprising at least two primers or probes, which hybridize under stringent conditions to at least two nucleic acids, wherein said at least two nucleic acids are selected from at least two groups of nucleic acids, wherein said groups consist of:
Group 1: SEQ ID NO 1
Group 2: a splice variant of Ensembl gene ID ENSG00000245750.3 selected from the group consisting of SEQ ID NO: 4, 5, 6, 7, 8, 9 and 10
Group 3: a splice variant of Ensembl gene ID ENSG00000255545.3 selected from the group SEQ ID NO: 26, 27, 28 and 29
Group 4: SEQ ID NO 3 and 11
Group 5: SEQ ID NO 12
Group 6: SEQ ID NO 24
Group 7: SEQ ID NO 36
Group 8: SEQ ID NO 38

### Claim 10 (depends on 9)

A kit according to claim 9 comprising at least 8 primers or probes, wherein said at least 8 primers or probes hybridize under stringent conditions to at least one nucleic acid of each of the eight groups.

### Claim 11

A method for the diagnosis and treatment of prostate cancer, comprising the steps of
a. analysing the expression levels of at least two nucleic acids in a sample of a patient, wherein said at least two nucleic acids are selected from at least two groups of nucleic acids, wherein said groups consist of:
Group 1: SEQ ID NO 1
Group 2: a splice variant of Ensembl gene ID ENSG00000245750.3 selected from the group consisting of SEQ ID NO: 4, 5, 6, 7, 8, 9 and 10
Group 3: a splice variant of Ensembl gene ID ENSG00000255545.3 selected from the group SEQ ID NO: 26, 27, 28 and 29
Group 4: SEQ ID NO 3 and 11
Group 5: SEQ ID NO 12
Group 6: SEQ ID NO 24
Group 7: SEQ ID NO 36
Group 8: SEQ ID NO 38
b. wherein, if the expression level of said at least two nucleic acids is above a defined threshold value, the sample is designated as prostate cancer positive; and
c. administering to the patient one or more Prostate Cancer Therapeutic Agents.

### Claim 12 (depends on 11)

The method of claim 11, wherein the Prostate Cancer Therapeutic Agents comprises: Docetaxel (Taxotere®); Cabazitaxel (Jevtana®); Mitoxantrone (Novantrone®); Estramustine (Emcyt®); Doxorubicin (Adriamycin®); Etoposide (VP-16); Vinblastine (Velban®); Paclitaxel (Taxol®); Carboplatin (Paraplatin®); Abiraterone acetate, Bicalutamide, Casodex, Degarelix, Enzalutamide, Goserelin acetate, Leuprolide acetate, Prednisone, Sipuleucel-T, Radium 223 dichloride and/or Vinorelbine (Navelbine®)
